Flash Finance

Vaidya Sane Ayurved Laboratories LimitedMADHAVBAUGCorporate

Healthcare Latest results: Mar 2026 8 quarters of data
Consolidated Standalone
₹167.95
MCap ₹177 Cr · P/E 19.3
Vaidya Sane Ayurved Laboratories Limited — Stock analysis & AI research Vaidya Sane Ayurved Laboratories Limited — Seasonality — best & worst months Vaidya Sane Ayurved Laboratories Limited — Live exchange announcements
🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹57 Cr
Sales · Mar 2026
+18.7% YoY
₹7 Cr
Operating Profit · Mar 2026
-24.5% YoY
11.9%
OPM % · Mar 2026
-36.7% YoY
₹4 Cr
Net Profit · Mar 2026
+38.5% YoY
₹3.95
EPS · Mar 2026
+23.1% YoY

📝 Vaidya Sane Ayurved Laboratories Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Vaidya Sane Ayurved Laboratories Limited reported revenue of ₹57 crore for the quarter ended March 2026 (Q4 FY26), up 18.7% from ₹48 crore in the same quarter last year.

Net profit rose 38.5% year-on-year to ₹4 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹3.95.

Operating profit stood at ₹7 crore — an operating margin (OPM) of 11.9%, compared with 18.8% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹107 crore with a net profit of ₹9 crore.

Valuation snapshot

At the current price of ₹167.95, MADHAVBAUG has a market capitalisation of ₹177 crore and a trailing P/E of about 19.3.

Within the Healthcare industry, it is the 17th-largest of the 22 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 66.34%, domestic institutional investors (DIIs) 0.00%, public shareholders 33.66% of Vaidya Sane Ayurved Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹177 Cr
Current Price ?
₹167.9
P/E ?
19.29below ind
Industry P/E ?
34.70
P/B ?
2.01
P/S ?
1.65
P/FCF ?
-88.29
Enterprise Value ?
₹180 Cr
EV/EBITDA ?
11.37
PEG ?
0.84
Earnings Yield ?
5.4%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹107 Cr
OPM ?
14.8%
Profit after tax (TTM) ?
₹9 Cr
EPS (TTM) ?
₹8.71
ROCE ?
15.0%
ROE ?
10.4%
ROA ?
8.7%
Growth
Sales — latest qtr ?
₹57 Cr
PAT — latest qtr ?
₹4 Cr
YoY qtr sales growth ?
18.7%
YoY qtr profit growth ?
38.5%
Sales growth (3y) ?
3%
Sales growth (5y) ?
N/A
Profit growth (3y) ?
23%
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹3 Cr
Debt to Equity ?
0.03
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
66.34%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-18.0%
Return 6 months ?
-9.8%

🗓️ Quarterly results (8 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026 YoY % QoQ %
Sales 4654514842485057 +18.7% —
Operating Profit 44326997 -24.5% —
Other Income 11111011 — —
Interest 00000101 -25.5% —
Depreciation 11222233 +56.4% —
Profit Before Tax 43215564 -13.2% —
Net Profit 32113354 +38.5% —
EPS 2.601.991.120.763.593.214.593.95 +23.1% —
OPM % 8.7% 6.9% 5.9% 4.2% 13.8% 18.8% 18.0% 11.9% -36.7% —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 11111111 +0.0%
Reserves 30455277 +48.1%
Borrowings 0213 +200.0%
Other Liabilities 14121314 +7.7%
Total Liabilities 557077105 +36.4%
Fixed Assets 21283435 +2.9%
CWIP 2212 +100.0%
Investments 15182140 +90.5%
Other Assets 17212028 +40.0%
Total Assets 557077105 +36.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 0-1115 -54.5%
Cash from Investing Activity 1-13-10-24 -140.0%
Cash from Financing Activity -115-117 +1800.0%
Net Cash Flow -11-0-2 —
Free Cash Flow -7-122-2 -200.0%
CFO/OP 31%-9%93%49% -47.3%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 22223135 +12.9%
Inventory Days —588270 -14.6%
Days Payable —101149127 -14.8%
Cash Conversion Cycle 22-20-37-21 +43.2%
Working Capital Days -257112 +1500.0%
ROCE % —6%18%15% -16.7%

👥 Shareholding (latest 4 periods)

Metric Mar 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 66.34%66.34%66.34%66.34% +0.0%
DIIs 0.00%0.21%0.00%0.00% —
Public 33.66%33.45%33.66%33.66% +0.0%
No. of Shareholders 787712700671 -4.1%

⚖️ Peer comparison

Industry: Healthcare · 22 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 VIJAYA Vijaya Diagnostic ₹1,507.80 15,530 82.7 857 187 42.3% 21.8% 19.5% 20.2% 22.8% 37.3%
2 METROPOLIS Metropolis Healthcare ₹596.30 12,370 61.1 1,710 203 24.7% 11.9% 23.6% 31.4% 16.6% 25.7%
3 HCG Healthcare Global ₹704.05 10,512 390.9 2,626 33 18.2% 1.3% 14.6% -53.3% 13.1% 175.3%
4 YATHARTH Yatharth Hospital ₹988.90 9,528 54.1 1,200 171 23.6% 14.3% 36.2% 31.6% 47.6% 16.2%
5 JLHL Jupiter Life ₹277.85 9,109 9.7 1,557 187 22.1% 12.0% 20.9% -6.7% 18.2% -14.5%
6 THYROCARE Thyrocare Technologies ₹555.45 8,841 50.0 876 176 32.1% 20.1% 20.8% 79.4% 24.3% 33.2%
7 KOVAI Kovai Medical ₹6,260.50 6,850 26.7 1,644 256 27.9% 15.6% 15.7% 16.7% 15.3% 20.6%
8 INDRAMEDCO Indraprastha Medical ₹363.20 3,330 17.7 1,524 188 18.0% 12.4% 9.3% 13.7% 11.3% 9.5%
9 KRSNAA Krsnaa Diagnostics ₹543.40 1,763 18.1 816 98 26.8% 12.0% 7.8% 31.0% 22.1% -19.3%
10 SURAKSHA Suraksha Diagnostic ₹311.85 1,624 45.3 325 35 31.4% 10.8% 23.1% 1.4% 20.7% 40.0%
11 SHALBY Shalby ₹132.15 1,418 38.0 1,176 37 12.1% 3.2% 5.0% 1683.0% 11.7% 36.7%
12 GPTHEALTH GPT Healthcare ₹157.90 1,296 27.4 491 48 18.5% 9.8% 15.1% -21.9% 17.8% 62.5%
13 LAXMIDENTL Laxmi Dental ₹196.21 1,080 35.0 287 31 16.2% 10.9% 16.0% -10.1% 13.2% 28.9%
14 NEPHROCARE Nephro Care ₹234.80 387 — — — — — — — 68.4% 347.7%
15 LOTUSEYE Lotus Eye ₹114.50 243 n/m 57 0 8.5% 0.3% 8.4% -89.1% 26.2% 13.0%
16 UNIHEALTH Unihealth Hospitals ₹121.00 190 6.5 132 46 40.9% 34.8% — — 104.6% 71.5%
17 MADHAVBAUG Vaidya Sane ₹148.00 156 19.1 147 8 11.4% 5.6% — — 116.1% 94.3%
18 MHHL Mohini Health ₹57.05 104 — 145 -17 -1.4% -11.7% — — -6.6% -1400.0%
19 MAITREYA Maitreya Medicare ₹120.65 82 — 45 -2 -1.0% -5.5% — — -5.2% -1720.0%
20 AATMAJ Aatmaj Healthcare ₹26.75 60 83.6 24 1 9.7% 2.9% — — 22.5% -39.4%
21 NIDAN Nidan Laborator. ₹33.00 46 30.6 26 2 19.0% 5.9% — — -11.2% -92.0%
22 ARTEMISMED Artemis Medicare ₹315.00 — 48.0 1,081 103 17.4% 9.6% 15.4% 25.9% 16.3% 30.9%
❓ Frequently asked questions
What was Vaidya Sane Ayurved Laboratories Limited's revenue in Q4 FY26?
Vaidya Sane Ayurved Laboratories Limited reported revenue of ₹57 crore for the quarter ended March 2026 (Q4 FY26), up 18.7% from ₹48 crore in the same quarter last year.
What was Vaidya Sane Ayurved Laboratories Limited's net profit in Q4 FY26?
Net profit rose 38.5% year-on-year to ₹4 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹3.95.
What is MADHAVBAUG's market capitalisation and P/E ratio?
At the current price of ₹167.95, MADHAVBAUG has a market capitalisation of ₹177 crore and a trailing P/E of about 19.3.
Who owns Vaidya Sane Ayurved Laboratories Limited? (shareholding pattern)
As of Mar 2026, promoters held 66.34%, domestic institutional investors (DIIs) 0.00%, public shareholders 33.66% of Vaidya Sane Ayurved Laboratories Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI